MutComFocal: An integrative approach to identifying recurrent and focal genomic alterations in tumor samples

BMC Systems Biology

Volumn 7, Issue , 2013, Pages

  Trifonov, Vladimir ^a,b   Pasqualucci, Laura ^c,d   Favera, Riccardo Dalla ^c,d   Rabadan, Raul ^a,b  

^a Department of Biomedical Informatics ^*  (United States)

^b Center for Computational Biology and Bioinformatics   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

Data integration; Driver genes; Tumorigenic mutations

Indexed keywords

ARID1B PROTEIN, HUMAN; CARRIER PROTEIN; DNA BINDING PROTEIN; IL31 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN DERIVATIVE; KLHL6 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP1 PROTEIN, HUMAN; ROBO2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; BAYES THEOREM; BIOLOGICAL MODEL; GENE DOSAGE; GENETIC ASSOCIATION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LARGE CELL LYMPHOMA; METHODOLOGY; POINT MUTATION; SYSTEMS BIOLOGY; TUMOR GENE;

BAYES THEOREM; CARRIER PROTEINS; DNA-BINDING PROTEINS; GENE DOSAGE; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTERLEUKINS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; LYMPHOMA, LARGE B-CELL, DIFFUSE; MODELS, GENETIC; POINT MUTATION; RECEPTORS, IMMUNOLOGIC; SYSTEMS BIOLOGY; TRANSCRIPTION FACTORS;

MLCS; MLOWN;

EID: 84875332216     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-7-25     Document Type: Article

References (32)

1. Hudson TJ, Anderson W. International network of cancer genome projects. Nature 2010, 464(7291):993-998. 10.1038/nature08987, 2902243, 20393554.
2. Guichard C, Amaddeo G. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012, 44(6):694-698. 10.1038/ng.2256, 22561517.
3. Lohr JG, Stojanov P. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012, 109(10):3879-3884. 10.1073/pnas.1121343109, 3309757, 22343534.
4. Pasqualucci L, Dominguez-Sola D. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471(7337):189-195. 10.1038/nature09730, 3271441, 21390126.
5. Pasqualucci L, Trifonov V. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011, 43(9):830-837. 10.1038/ng.892, 3297422, 21804550.
6. Puente XS, Pinyol M. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475(7354):101-105. 10.1038/nature10113, 3322590, 21642962.
7. Beroukhim R, Getz G. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007, 104(50):20007-20012. 10.1073/pnas.0710052104, 2148413, 18077431.
8. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005, 106(4):1164-1174. 10.1182/blood-2005-02-0687, 15855278.
9. Akavia UD, Litvin O. An integrated approach to uncover drivers of cancer. Cell 2010, 143(6):1005-1017. 10.1016/j.cell.2010.11.013, 3013278, 21129771.
10. Morin RD, Mendez-Lago M. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476(7360):298-303. 10.1038/nature10351, 3210554, 21796119.
11. Challa-Malladi M, Lieu YK. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20(6):728-40. 10.1016/j.ccr.2011.11.006, 22137796.
12. Pasqualucci L, Compagno M. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006, 203(2):311-317. 10.1084/jem.20052204, 2118216, 16492805.
13. Compagno M, Lim WK. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459(7247):717-21. 10.1038/nature07968, 2973325, 19412164.
14. Ohta M, Inoue H. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84(4):587-597. 10.1016/S0092-8674(00)81034-X, 8598045.
15. Huang H, Qian J. FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. Oncogene 1998, 16(18):2311-2319. 10.1038/sj.onc.1200202, 9620548.
16. Rui L, Emre NC. Cooperative epigenetic modulation by cancer amplicon genes. Cancer cell 2010, 18(6):590-605. 10.1016/j.ccr.2010.11.013, 3049192, 21156283.
17. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011, 118(10):2659-2669. 10.1182/blood-2011-05-326538, 21700770.
18. McDonald JD, Daneshvar L. Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma. Genomics 1994, 23(1):229-232. 10.1006/geno.1994.1481, 7829075.
19. Nagl NG, Zweitzig DR. The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. Cancer Res 2006, 66(3):1289-1293. 10.1158/0008-5472.CAN-05-3427, 16452181.
20. Steidl C, Shah SP. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471(7338):377-381. 10.1038/nature09754, 21368758.
21. Ghosh S, Ghosh A. Alterations of ROBO1/DUTT1 and ROBO2 loci in early dysplastic lesions of head and neck: clinical and prognostic implications. Hum Genet 2009, 125(2):189-198. 10.1007/s00439-008-0610-9, 19104841.
22. Chen Y, Sullivan C. A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood 2011, 118(2):390-400. 10.1182/blood-2010-11-316760, 3138690, 21596859.
23. Houldsworth J, Olshen AB. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood 2004, 103(5):1862-1868. 10.1182/blood-2003-04-1359, 14615382.
24. Lenz G, Wright GW. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008, 105(36):13520-13525. 10.1073/pnas.0804295105, 2533222, 18765795.
25. Danovi D, Meulmeester E. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004, 24(13):5835-43. 10.1128/MCB.24.13.5835-5843.2004, 480894, 15199139.
26. Pasqualucci L, Neumeister P. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001, 412(6844):341-6. 10.1038/35085588, 11460166.
27. Lenz G, Davis RE. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319(5870):1676-9. 10.1126/science.1153629, 18323416.
28. Morin RD, Johnson NA. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42(2):181-5. 10.1038/ng.518, 2850970, 20081860.
29. Iqbal J, Sanger WG. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004, 65(1):159-66.
30. Kroll J, Shi X. The BTB-kelch Protein KLHL6 Is Involved in B-Lymphocyte Antigen Receptor Signaling and Germinal Center Formation. Mol Cell Biol 2005, 25(19):8531-8540. 10.1128/MCB.25.19.8531-8540.2005, 1265761, 16166635.
31. Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 2008, 19(5-6):347-56. 2659402, 18926762.
32. Langlois B, Perrot G. LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 2010, 5(7):e11584. 10.1371/journal.pone.0011584, 2904376, 20644732.